Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

Amber Tong

By the time the FDA approved Luxturna — the pioneering gene therapy for an inherited retinal disease — Henry Klassen had been researching and treating the group …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

Amber Tong

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Can prog­en­i­tor cells go fur­ther than gene ther­a­py in reti­nal dis­or­ders? A biotech's an­swer shines in PhI­Ib

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb